STOCK TITAN
  1. Home
  2. Sec-filings
  3. PHVS
  4. [Form 4] Pharvaris N.V. Insider Trading Activity

Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pharvaris N.V. Chief Medical Officer Lu Peng reported a series of option exercises and related share sales. On June 25–26, 2026, she exercised stock options covering 29,700 shares of common stock at a $2.59 exercise price and sold 29,700 shares in open-market transactions under a Rule 10b5-1 trading plan using cashless exercises. Reported weighted average sale prices were about $34.45, $35.09, and $34.00, each reflecting multiple trades within narrow price ranges. Following these transactions, Peng holds 65,631 shares of Pharvaris common stock directly.

Positive

  • None.

Negative

  • None.
Insider Lu Peng
Role Chief Medical Officer
Sold 29,700 shs ($1.02M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 14,700 $0.00 --
Exercise Common Stock 14,700 $2.59 $38K
Sale Common Stock 14,700 $34.0032 $500K
Exercise Stock Option (Right to Buy) 15,000 $0.00 --
Exercise Common Stock 15,000 $2.59 $39K
Sale Common Stock 11,600 $34.4547 $400K
Sale Common Stock 3,400 $35.0913 $119K
Holdings After Transaction: Stock Option (Right to Buy) — 175,308 shares (Direct, null); Common Stock — 80,331 shares (Direct, null)
Footnotes (1)
  1. This is a scheduled exercise and sale from 10b5-1 trading plan. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to $34.98. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to 34.02. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
Shares sold 29,700 shares Total common shares sold in open-market transactions on June 25–26, 2026
Shares exercised 29,700 shares Common shares acquired through stock option exercises on June 25–26, 2026
Exercise price $2.59 per share Stock option exercise price for 29,700 common shares
Sale price 1 $34.4547 per share Weighted average sale price for 11,600 shares of common stock on June 25, 2026
Sale price 2 $35.0913 per share Weighted average sale price for 3,400 shares of common stock on June 25, 2026
Sale price 3 $34.0032 per share Weighted average sale price for 14,700 shares of common stock on June 26, 2026
Post-transaction holdings 65,631 shares Common stock directly owned by Lu Peng after reported transactions
Rule 10b5-1 trading plan financial
"transactions on the reported date pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
cashless exercise financial
"shares were sold in connection with the exercise of stock options in a cashless exercise transaction"
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
weighted average sale price financial
"The reported price represents a weighted average sale price for shares sold in multiple transactions"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lu Peng
(Last)(First)(Middle)
1 CRANBERRY HILL SUITE 400
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/25/2026M(1)15,000A$2.5980,631D
Common Stock06/25/2026S(1)11,600D$34.4547(2)69,031D
Common Stock06/25/2026S(1)3,400D$35.0913(3)65,631D
Common Stock06/26/2026M(1)14,700A$2.5980,331D
Common Stock06/26/2026S(1)14,700D$34.0032(4)65,631D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2.5906/25/2026M(1)15,000 (5)02/03/2030Common Stock15,000$0190,008D
Stock Option (Right to Buy)$2.5906/26/2026M(1)14,700 (5)02/03/2030Common Stock14,700$0175,308D
Explanation of Responses:
1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to $34.98. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
4. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $34.00 to 34.02. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
5. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
/s/ Marnus Nel, Attorney-in-Fact for Peng Lu06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pharvaris (PHVS) report for Lu Peng?

Pharvaris reported that Chief Medical Officer Lu Peng exercised stock options for 29,700 shares and sold 29,700 shares of common stock. These transactions occurred on June 25–26, 2026 as part of pre-arranged activity under a Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares does Lu Peng own after these Form 4 transactions?

After the reported transactions, Lu Peng directly owns 65,631 shares of Pharvaris common stock. This figure reflects her holdings following the option exercises and related open-market sales disclosed for June 25–26, 2026 on the Form 4 filing.

What prices were Pharvaris (PHVS) shares sold for in Lu Peng’s June 2026 trades?

The filing lists weighted average sale prices of about $34.00, $34.45, and $35.09 per share. Each represents multiple trades within narrow ranges, all executed pursuant to a Rule 10b5-1 trading plan and linked to cashless stock option exercises.

What was the exercise price of Lu Peng’s Pharvaris (PHVS) stock options?

Lu Peng’s exercised stock options carried a $2.59 per share exercise price. She exercised options covering a total of 29,700 shares of Pharvaris common stock on June 25–26, 2026, then sold the same number of shares in related open-market transactions.

Was Lu Peng’s Pharvaris (PHVS) stock sale pre-planned under Rule 10b5-1?

Yes. The footnotes state the sales were executed pursuant to a Rule 10b5-1 trading plan. Such plans pre-schedule trades, meaning the timing of these June 2026 cashless exercise and sale transactions was established in advance rather than decided opportunistically.

What is meant by cashless exercise in Lu Peng’s Pharvaris (PHVS) Form 4?

The filing notes that shares were sold in connection with option exercises in a cashless exercise transaction. In this structure, part or all of the exercised shares are sold immediately, and sale proceeds cover the $2.59 per share exercise cost and related obligations.